Adjuvant trastuzumab for breast cancer: Advent of pharmacogenetics raises many issuesBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7526.1202-a (Published 17 November 2005) Cite this as: BMJ 2005;331:1202
- Hazel Thornton (firstname.lastname@example.org), honorary visiting fellow
- Department of Health Sciences, University of Leicester “Saionara,” Colchester CO5 7EA
EDITOR—Kell and Power [previous letter] at last clarify for everyone that at least 20% of patients with positive immunochemical results will not benefit from trastuzumab.1 These are expensive false positives at £20 000 yearly per patient, both for the health system and for patients' quality of life—or, indeed, life at all, bearing in mind the death rate …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial